Early prolonged neutrophil activation in critically ill patients with sepsis.

IF 2.8 4区 医学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Innate Immunity Pub Date : 2021-02-01 Epub Date: 2021-01-18 DOI:10.1177/1753425920980078
Sanna Törnblom, Sara Nisula, Suvi T Vaara, Meri Poukkanen, Sture Andersson, Ville Pettilä, Eero Pesonen
{"title":"Early prolonged neutrophil activation in critically ill patients with sepsis.","authors":"Sanna Törnblom,&nbsp;Sara Nisula,&nbsp;Suvi T Vaara,&nbsp;Meri Poukkanen,&nbsp;Sture Andersson,&nbsp;Ville Pettilä,&nbsp;Eero Pesonen","doi":"10.1177/1753425920980078","DOIUrl":null,"url":null,"abstract":"<p><p>We hypothesised that plasma concentrations of biomarkers of neutrophil activation and pro-inflammatory cytokines differ according to the phase of rapidly evolving sepsis. In an observational study, we measured heparin-binding protein (HBP), myeloperoxidase (MPO), IL-6 and IL-8 in 167 sepsis patients on intensive care unit admission. We prospectively used the emergence of the first sepsis-associated organ dysfunction (OD) as a surrogate for the sepsis phase. Fifty-five patients (of 167, 33%) developed the first OD > 1 h before, 74 (44%) within ± 1 h, and 38 (23%) > 1 h after intensive care unit admission. HBP and MPO were elevated at a median of 12 h before the first OD, remained high up to 24 h, and were not associated with sepsis phase. IL-6 and IL-8 rose and declined rapidly close to OD emergence. Elevation of neutrophil activation markers HBP and MPO was an early event in the evolution of sepsis, lasting beyond the subsidence of the pro-inflammatory cytokine reaction. Thus, as sepsis biomarkers, HBP and MPO were not as prone as IL-6 and IL-8 to the effect of sample timing.</p>","PeriodicalId":13676,"journal":{"name":"Innate Immunity","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1753425920980078","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innate Immunity","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1177/1753425920980078","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 6

Abstract

We hypothesised that plasma concentrations of biomarkers of neutrophil activation and pro-inflammatory cytokines differ according to the phase of rapidly evolving sepsis. In an observational study, we measured heparin-binding protein (HBP), myeloperoxidase (MPO), IL-6 and IL-8 in 167 sepsis patients on intensive care unit admission. We prospectively used the emergence of the first sepsis-associated organ dysfunction (OD) as a surrogate for the sepsis phase. Fifty-five patients (of 167, 33%) developed the first OD > 1 h before, 74 (44%) within ± 1 h, and 38 (23%) > 1 h after intensive care unit admission. HBP and MPO were elevated at a median of 12 h before the first OD, remained high up to 24 h, and were not associated with sepsis phase. IL-6 and IL-8 rose and declined rapidly close to OD emergence. Elevation of neutrophil activation markers HBP and MPO was an early event in the evolution of sepsis, lasting beyond the subsidence of the pro-inflammatory cytokine reaction. Thus, as sepsis biomarkers, HBP and MPO were not as prone as IL-6 and IL-8 to the effect of sample timing.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
危重症脓毒症患者早期延长中性粒细胞活化。
我们假设中性粒细胞激活和促炎细胞因子的生物标志物的血浆浓度根据快速发展的败血症的阶段而不同。在一项观察性研究中,我们测量了167名重症监护病房入院的败血症患者的肝素结合蛋白(HBP)、髓过氧化物酶(MPO)、白细胞介素6和白细胞介素8。我们前瞻性地使用首次脓毒症相关器官功能障碍(OD)的出现作为脓毒症阶段的替代指标。55例(167.33%)患者在入住重症监护室前> 1 h发生首次用药过量,74例(44%)在入住前±1 h内发生,38例(23%)在入住后> 1 h。HBP和MPO在第一次用药前12小时中位数升高,并在24小时内保持高水平,与脓毒症期无关。IL-6和IL-8在OD出现前后迅速上升和下降。中性粒细胞活化标志物HBP和MPO的升高是脓毒症演变的早期事件,持续时间超过促炎细胞因子反应的消退。因此,作为脓毒症的生物标志物,HBP和MPO不像IL-6和IL-8那样容易受到采样时间的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Innate Immunity
Innate Immunity 生物-免疫学
CiteScore
7.20
自引率
0.00%
发文量
20
审稿时长
6-12 weeks
期刊介绍: Innate Immunity is a highly ranked, peer-reviewed scholarly journal and is the official journal of the International Endotoxin & Innate Immunity Society (IEIIS). The journal welcomes manuscripts from researchers actively working on all aspects of innate immunity including biologically active bacterial, viral, fungal, parasitic, and plant components, as well as relevant cells, their receptors, signaling pathways, and induced mediators. The aim of the Journal is to provide a single, interdisciplinary forum for the dissemination of new information on innate immunity in humans, animals, and plants to researchers. The Journal creates a vehicle for the publication of articles encompassing all areas of research, basic, applied, and clinical. The subject areas of interest include, but are not limited to, research in biochemistry, biophysics, cell biology, chemistry, clinical medicine, immunology, infectious disease, microbiology, molecular biology, and pharmacology.
期刊最新文献
Innate lymphoid cells and infectious diseases. Selective IgG binding to the LPS glycolipid core found in bovine colostrum, or milk, during Escherichia coli mastitis influences endotoxin function The in vitro effect of myeloperoxidase oxidized LDL on THP-1 derived macrophages. A pilot study of monocytes in relapsing remitting multiple sclerosis: Correlation with disease activity. CRISPR activation as a platform to identify interferon stimulated genes with anti-viral function.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1